XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and License Agreement - Additional Information (Details) - Bristol-Myers Squibb Company - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2020
May 30, 2020
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
May 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Non-refundable upfront payment received     $ 50,000,000     $ 50,000,000    
Options to License Druggable Target Lesions                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Non-refundable upfront payment received     31,148,000     31,148,000    
Collaboration and License Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Collaboration term expiration period   42 months            
Initial nonrefundable upfront fee received $ 50,000,000.0              
Non-refundable upfront payment received               $ 50,000,000.0
Deferred revenue recognized     700,000   $ 300,000 1,100,000 $ 400,000  
Revenue Recognized     0 $ 6,500,000 $ 0 0 $ 0  
Deferred revenue     41,400,000 42,500,000   41,400,000    
Deferred revenue, current     2,800,000 2,900,000   2,800,000    
Deferred revenue, noncurrent     $ 38,600,000 $ 39,600,000   $ 38,600,000    
Collaboration and License Agreement | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Milestone payments entitled to be received               301,000,000.0
Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Milestone payments entitled to be received               176,000,000.0
Collaboration and License Agreement | Maximum | Commercial Milestones                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Milestone payments entitled to be received               $ 125,000,000.0